Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis

Published:2022-03-17 Issue:2 Volume:76 Page:253-262
ISSN:1559-0100
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Cheng Yonglang,Li Tongxi,Tan Peng,Du Yichao,Huang Zhiwei,Shi Hao,Cai Tianying,Chen Yifan,Fu Wenguang

Funder

Department of Science and Technology of Sichuan Province

Luzhou Municipal Peoples Government-Southwest Medical University Science and Technology Strategic Cooperation Project

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s12020-022-03025-8.pdf

Reference22 articles.

1. M.J. Ariza, J. Rioja, D. Ibarretxe, A. Camacho, J.L. Díaz-Díaz, A. Mangas et al. Spanish Dyslipidemia Registry. Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. J. Clin. Lipidol. 12(6), 1482–1492.e3 (2018)

2. C.V atier, M.C.V antyghem, C. Storey, I. Jéru, S. Christin-Maitre, B. Fève et al. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases. Curr. Med. Res. Opin. 35(3), 543–552 (2019)

3. A. Chait, R.H. Eckel, The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment. Ann. Intern. Med. 170(9), 626–634 (2019). Epub 2019 Apr 30 https://doi.org/10.7326/M19-0203. Epub 2019 Apr 30

4. L. D’Erasmo, S. Bini, M. Arca, Rare treatments for rare dyslipidemias: new perspectives in the treatment of homozygous familial hypercholesterolemia (HoFH) and familial chylomicronemia syndrome (FCS). Curr. Atheroscler Rep. 23(Sep 11), 65 (2021). https://doi.org/10.1007/s11883-021-00967-8

5. M. Larsson, C.M. Allan, R.S. Jung, P.J. Heizer, A.P. Beigneux, S.G. Young, L.G. Fong, Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL. J. Lipid Res. 58(9), 1893–1902 (2017). Epub 2017 Jul 10 https://doi.org/10.1194/jlr.M078220. Epub 2017 Jul 10

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of the novel RNA interference therapies for hypertriglyceridemia and mixed hyperlipidemia management: a systematic review and meta-analysis;Endocrine Practice;2024-09

2. Inhibitors of apolipoprotein C3, triglyceride levels, and risk of pancreatitis: a systematic review and meta-analysis;Reviews in Endocrine and Metabolic Disorders;2024-07-13

3. Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table;Journal of Clinical Lipidology;2024-07

4. Assessment of the global and national market for lipid modifying agents: retrospective and innovation;Сибирский научный медицинский журнал;2023-08-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3